Tesamorelin and blood work: what to test and when

Last updated 2026-07-25

Why does tesamorelin require blood work at all?

Tesamorelin is a growth hormone releasing hormone (GHRH) analogue. It doesn't put growth hormone directly into the body; it tells the pituitary to make more of its own ^{[1] [2]}. That mechanism is exactly why blood work matters so much more here than with a lot of other injectables. When you push GH output up, insulin-like growth factor 1 (IGF-1) goes up too, since IGF-1 is the downstream signal the liver makes in response to GH. The phase 3 trials that got tesamorelin approved as Egrifta tracked IGF-1 as a primary pharmacodynamic marker, not an afterthought ^[3] . Glucose handling is the other big one: GH has a well-documented tendency to work against insulin, and the pooled phase 3 data in HIV patients with excess abdominal fat specifically flagged glucose changes as something to watch . So blood work isn't a formality here. It's the tool that catches the two things this drug is most likely to do wrong: push IGF-1 too high, or nudge blood sugar the wrong direction. Without labs, you're guessing.

What baseline labs should you get before starting tesamorelin?

Before the first dose, get a fasting IGF-1, fasting glucose or HbA1c, and a liver panel. This is the same set of measures the major trials used to characterize patients at entry and to judge safety over time . IGF-1 baseline matters because tesamorelin is meant to raise it toward the upper end of the normal range for age, not blow past it. Without knowing where you started, a follow-up number is hard to interpret. Fasting glucose and HbA1c matter because the FDA-approved indication is specifically in HIV patients with lipodystrophy, a population that already runs a higher background rate of insulin resistance ^[4] . If someone starts with borderline glucose control, that's worth knowing before adding a GH-axis drug. A liver panel is worth a look too. Tesamorelin's most-studied secondary benefit is on liver fat: one randomized trial found it reduced hepatic fat fraction and, in a related analysis, reduction in visceral fat tracked with improved liver enzymes ^[5] . That means liver enzymes are a marker you'd actually expect to move in a favorable direction, so it helps to have a starting point. For dosing mechanics rather than labs, see how to reconstitute tesamorelin and tesamorelin how to inject.

What does IGF-1 monitoring actually show, and what counts as too high?

IGF-1 is the main lab used to confirm tesamorelin is doing what it's supposed to do, biologically. The phase 3 program in HIV-associated lipodystrophy showed IGF-1 increases with treatment, consistent with the drug's mechanism of stimulating endogenous GH release . There isn't a single universal 'too high' number quoted across all sources; normal IGF-1 reference ranges are age- and lab-specific, and the trials generally aimed to keep IGF-1 within the normal range for age rather than push it above. The practical read: a clinician following tesamorelin therapy checks IGF-1 against the lab's own age-adjusted reference range, not a fixed cutoff pulled from somewhere else. If IGF-1 runs persistently above the upper limit of normal, that's typically a signal to reassess dose or continue therapy, a decision that belongs with the prescribing clinician, not a DIY call. This is also the lab most likely to show whether the drug is even being handled and dosed correctly, which is part of why timing and technique matter; see best time to take tesamorelin peptide.

Does tesamorelin affect blood sugar and does that need monitoring?

Yes. Glucose is one of the two lab values the major trials paid closest attention to, alongside IGF-1 . GH-axis stimulation has a known tendency to raise blood glucose and can worsen insulin sensitivity, which is a mechanistic, expected effect rather than a rare surprise. A meta-analysis of randomized controlled trials of tesamorelin in HIV-associated lipodystrophy looked specifically at metabolic and safety outcomes alongside body composition and hepatic fat changes, treating glucose control as a core safety endpoint worth pooling across studies ^[6]. That framing (safety outcome, not side detail) tells you how seriously trial designers took it. Practical takeaway: fasting glucose or HbA1c at baseline, then periodic rechecks, is a reasonable monitoring cadence for anyone on tesamorelin, and it's non-negotiable for anyone who already runs pre-diabetic or diabetic numbers. This is a conversation to have with a prescriber before starting, not after.

How often should labs be repeated once you're on tesamorelin?

There's no single FDA-mandated testing calendar published in consumer-facing form, but the pattern from trial design and clinical practice points to baseline, then a recheck at roughly 3 to 6 months, then periodically after that if therapy continues. The logic: IGF-1 and glucose changes from GHRH stimulation show up within weeks to a couple of months of steady dosing, not immediately after the first injection. A single early recheck catches most problems before they compound. After that, spacing labs out to every few months (paired with clinical follow-up) mirrors how the safety extension data in the phase 3 program was structured, tracking patients over extended treatment periods rather than just at trial's end . If you're mid-cycle and wondering how long a course typically runs before reassessment, that's a separate but related question covered in tesamorelin cycle length.

What liver-related blood work is relevant to tesamorelin?

Liver enzymes (ALT, AST) and, where relevant, hepatic fat imaging are relevant because tesamorelin has real trial data on liver fat, more than visceral fat. A randomized, double-blind, multicenter trial found tesamorelin reduced hepatic fat in HIV patients with NAFLD, one of the more specific secondary findings in the tesamorelin literature ^[5]. Separately, visceral fat reduction in a phase 3 population was associated with improved liver enzymes , and later mechanistic work used transcriptomic and proteomic approaches to map out how tesamorelin's effects show up in liver tissue at a molecular level ^{[7] [8]}. None of this makes tesamorelin an approved fatty liver drug; the approved indication is HIV-associated lipodystrophy, and NAFLD improvement is a secondary trial finding, not the label indication. For blood work purposes, that means a liver panel at baseline and at follow-up is reasonable, both to catch any adverse liver signal and because, if the trial pattern holds, you might actually see enzyme improvement rather than harm.

Are there other labs or exams worth doing alongside blood work?

A few things sit next to the blood panel rather than in it. Local injection-site reactions were the most common adverse event across the phase 3 program, so a visual skin check matters as much as a blood draw . Fluid retention, joint pain, and paresthesia (numbness or tingling) were also reported in trial safety data, and those are symptom-based, not something a lab catches directly ^[3] . Antibody formation against tesamorelin was studied in the trial program too, since any peptide can trigger an immune response; this doesn't require blood work most patients would order on their own, but it's part of why prescriber follow-up (not self-monitoring alone) is the safer pattern . None of these replace the core three: IGF-1, glucose/A1c, liver enzymes. But a full check-in includes a look at injection sites and a conversation about symptoms, more than a lab requisition. See tesamorelin injection sites for site rotation and reaction management.

Is tesamorelin FDA approved, and does that change what labs are 'required'?

Yes, tesamorelin is FDA approved under the brand name Egrifta, specifically for reducing excess abdominal fat in HIV-infected patients with lipodystrophy ^{[2] [9] [10]}. That's the only approved indication. That narrow approval matters for blood work because the monitoring pattern described in this article comes from trials done in that specific population: adults with HIV and excess visceral abdominal fat, most already managing HIV with antiretroviral therapy. A 2024 study looked specifically at efficacy and safety of tesamorelin in people with HIV on integrase inhibitors, a more modern antiretroviral regimen than what some earlier trials used ^[11]. That's a meaningfully different starting metabolic picture than someone using tesamorelin off-label for general fat loss or anti-aging purposes, and it's a reason to be cautious about assuming the same lab thresholds apply identically outside the approved population. Off-label use isn't illegal, but it also isn't backed by the same depth of monitoring data. Anyone using tesamorelin outside the approved lipodystrophy indication should treat the trial-derived monitoring pattern as a floor, not a guarantee that their situation is comparable.

What did the phase 3 trials actually find on safety, in plain terms?

The pooled analysis of two multicenter, double-blind, placebo-controlled phase 3 trials (with safety extension data) is the single most important source for anyone asking what tesamorelin does to the body over time . It covered HIV-infected patients with excess abdominal fat and tracked outcomes both during the core trial and through an extension period. A 2026 meta-analysis of randomized controlled trials pooled body composition, hepatic fat, metabolic, and safety outcomes specifically for tesamorelin in HIV-associated lipodystrophy, giving a more consolidated picture than any single trial ^[6]. This is useful because individual trials vary in size and duration; pooling them evens out some of that noise. Inflammatory markers were also studied: one analysis looked at how tesamorelin's inflammatory marker changes related to visceral fat reduction, suggesting the metabolic benefit and the inflammatory change move together rather than independently . That's a mechanistic detail, useful for understanding why the drug works, less useful as a standalone monitoring target for routine blood work.

How does tesamorelin's blood work compare to monitoring for other GH-axis peptides?

This is a fair comparison question, and the honest answer is that tesamorelin has more monitoring infrastructure behind it than most peptides in this space, precisely because it went through FDA phase 3 trials rather than staying in compounding-only or research-use territory. | Monitoring aspect | Tesamorelin (FDA-approved, Egrifta) | Unapproved GH-axis peptides |

What symptoms should prompt an unscheduled blood test?

New or worsening joint pain, unusual swelling in the hands or feet, tingling or numbness, or symptoms of high blood sugar (excess thirst, frequent urination, fatigue) are reasonable triggers for an earlier-than-scheduled check. These map to adverse events reported in the phase 3 safety data: fluid retention, arthralgia, and paresthesia were among the documented effects, alongside injection-site reactions ^[3] . None of these symptoms are rare curiosities; they're on the list because trial patients experienced them at rates high enough to report. If any of them show up, checking IGF-1 and glucose sooner than the routine follow-up interval is sensible, and it's worth flagging to whoever prescribed the tesamorelin rather than waiting for the next scheduled visit.

Where do you actually get tesamorelin and does that affect monitoring quality?

Tesamorelin as Egrifta is a prescription drug, and getting it through a provider-reviewed pathway is what keeps the blood work loop intact: baseline labs, a prescriber who reviews them, dosing decisions tied to actual lab results rather than guesswork. Tesamorelin Co works with a provider-reviewed process and names its fulfilling pharmacy partner rather than compounding or manufacturing anything itself; the company's role is connecting the monitoring and prescribing pathway, not producing the drug. That distinction matters because sourcing without a monitoring relationship defeats the purpose of everything covered above. A vial without a lab order attached to it is a vial you're dosing blind. If cost is part of what's driving the sourcing decision, tesamorelin cost breaks down what the drug and the associated visits typically run.

Frequently asked questions

What blood tests are needed before starting tesamorelin?

Baseline labs typically include fasting IGF-1, fasting glucose or HbA1c, and a liver panel (ALT/AST). These mirror the markers tracked in the phase 3 trials that led to tesamorelin's approval as Egrifta for HIV-associated lipodystrophy, and they give you a starting point to judge whether the drug is working and whether it's raising glucose or IGF-1 too far ^[20].

How often should you check IGF-1 while on tesamorelin?

There's no single published mandatory schedule, but a reasonable pattern based on trial design is a recheck around 3 to 6 months after starting, then periodically if treatment continues. IGF-1 is the main marker confirming the drug's GHRH mechanism is working as intended ^[4][20].

Can tesamorelin cause high blood sugar?

It can. GH-axis stimulation is known to work against insulin sensitivity, and glucose was one of the core safety measures tracked in the phase 3 program ^[20]. Fasting glucose or HbA1c monitoring at baseline and follow-up is standard practice, and it's especially important for anyone with pre-existing insulin resistance.

Does tesamorelin affect liver enzymes?

Trial data suggests it can improve them. Visceral fat reduction with tesamorelin has been associated with improved liver enzymes in HIV patients, and a separate randomized trial found tesamorelin reduced hepatic fat in patients with NAFLD ^[19][22]. Liver enzymes are still worth checking at baseline to have a comparison point.

Is tesamorelin FDA approved?

Yes. Tesamorelin is FDA approved under the brand name Egrifta specifically to reduce excess abdominal fat in HIV-infected patients with lipodystrophy ^[4][10][16]. That is the only approved indication; any other use is off-label, including general fat loss or anti-aging use.

What is IGF-1 and why does it matter for tesamorelin monitoring?

IGF-1 is a hormone the liver produces in response to growth hormone. Since tesamorelin works by stimulating the pituitary to release more GH, IGF-1 rises as a downstream marker confirming the drug is active ^[4][20]. Monitoring it helps a clinician judge whether dosing is appropriate or running too high.

What were the most common side effects seen in tesamorelin trials?

Injection-site reactions were the most commonly reported adverse event in the pooled phase 3 trials, along with joint pain (arthralgia), fluid retention, and paresthesia (tingling or numbness) ^[11][20][23]. Blood sugar and IGF-1 changes were tracked separately as metabolic safety endpoints rather than reported as typical side effects.

Do you need blood work if you're only using tesamorelin short term?

Baseline labs are still worth getting even for a short course, since IGF-1 and glucose changes from GHRH stimulation can appear within weeks. A single follow-up check partway through or at the end of a short cycle is a reasonable minimum, though longer courses warrant more frequent monitoring.

Can tesamorelin be detected in a drug test?

Analytical methods for detecting GHRH synthetic analogues, including tesamorelin, have been developed and are used in anti-doping contexts. A 2021 review in Drug Testing and Analysis covers advances in detecting this drug class ^[8]. This is separate from routine clinical blood work, which looks at IGF-1 and metabolic markers, not detection of the peptide itself.

Does tesamorelin require monitoring for antibody formation?

Antibody development was assessed in the phase 3 program as part of standard safety evaluation for a peptide therapeutic ^[20]. This isn't typically part of routine patient-ordered blood work; it's the kind of monitoring built into clinical trial protocols and overseen by a prescriber rather than something patients need to request on their own.

Is tesamorelin safe for people without HIV who want visceral fat reduction?

The FDA-approved indication and the phase 3 safety data are specific to HIV patients with lipodystrophy. Using tesamorelin for visceral fat reduction without HIV-associated lipodystrophy is off-label, and there isn't the same depth of trial-grade safety monitoring data for that population, so extra caution and provider oversight matter more, not less.

What lab pattern do the phase 3 trials suggest for long-term use?

The trials included safety extension data tracking patients over an extended treatment period beyond the initial trial window, suggesting ongoing periodic monitoring (IGF-1, glucose, liver enzymes) rather than a one-time baseline-and-done approach for anyone continuing tesamorelin long term ^[20].

Sources

1. PubMed, Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians (PMID 41476424): Peptide therapies used in orthopaedic and sports medicine vary widely in evidence quality, and clinicians need to distinguish which have trial-grade safety data.
2. PubMed, Tesamorelin (PMID 21283099, Nature Reviews Drug Discovery 2011): Tesamorelin is a growth hormone releasing hormone (GHRH) analogue that stimulates endogenous GH release rather than supplying GH directly.
3. PubMed, Tesamorelin (PMID 31644039, 2012): Tesamorelin is FDA approved as Egrifta for reducing excess abdominal fat in HIV-infected patients with lipodystrophy, working via GHRH-stimulated GH release.
4. PubMed, Efficacy and safety of tesamorelin in people with HIV on integrase inhibitors (PMID 38905488, AIDS 2024): A 2024 study evaluated tesamorelin efficacy and safety specifically in people with HIV using integrase inhibitor-based antiretroviral therapy.
5. PubMed, Advances in the detection of growth hormone releasing hormone synthetic analogs (PMID 34665524, Drug Testing and Analysis 2021): Analytical methods have been developed to detect GHRH synthetic analogues such as tesamorelin in anti-doping and forensic contexts.
6. PubMed, Tesamorelin: a review of its use in the management of HIV-associated lipodystrophy (PMID 21668043, Drugs 2011): Tesamorelin's approved use is specifically in the management of HIV-associated lipodystrophy.
7. PubMed, Tesamorelin: a growth hormone-releasing factor analogue for HIV-associated lipodystrophy (PMID 22298602, Annals of Pharmacotherapy 2012): IGF-1 monitoring and adverse events including arthralgia and paresthesia were documented as part of tesamorelin's safety profile.
8. PubMed, Effects of tesamorelin on hepatic transcriptomic signatures in HIV-associated NAFLD (PMID 32701508, JCI Insight 2020): Tesamorelin's effects on liver tissue have been mapped using transcriptomic approaches in HIV-associated NAFLD.
9. PubMed, Approach to the Patient With Lipodystrophy (PMID 35137140, JCEM 2022): Lipodystrophy populations, including those with HIV-associated lipodystrophy, carry elevated background rates of insulin resistance.
10. PubMed, Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions (PMID 42123471, IJMS 2026): Tesamorelin's approved metabolic/endocrine application is reviewed alongside its safety profile in the peptide therapeutics literature.
11. PubMed, Body composition, hepatic fat, metabolic, and safety outcomes of Tesamorelin (PMID 41545261, Obesity Research & Clinical Practice 2026): A meta-analysis of randomized controlled trials pooled body composition, hepatic fat, metabolic, and safety outcomes for tesamorelin in HIV-associated lipodystrophy.
12. PubMed, Delineating tesamorelin response pathways in HIV-associated NAFLD using targeted proteomic and transcriptomic approach (PMID 34006921, Scientific Reports 2021): Proteomic and transcriptomic analysis has been used to characterize tesamorelin's response pathways in HIV-associated NAFLD.
13. PubMed, Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial (PMID 31611038, Lancet HIV 2019): A randomized, double-blind, multicenter trial found tesamorelin reduced hepatic fat in HIV patients with NAFLD.
14. PubMed, Effects of tesamorelin (TH9507) in HIV-infected patients with excess abdominal fat: pooled analysis of two phase 3 trials with safety extension data (PMID 20554713, JCEM 2010): Pooled phase 3 trial and safety extension data tracked IGF-1, glucose, and adverse events including injection-site reactions in HIV patients with excess abdominal fat.
15. PubMed, Visceral fat reduction with tesamorelin is associated with improved liver enzymes in HIV (PMID 28832410, AIDS 2017): Visceral fat reduction achieved with tesamorelin was associated with improved liver enzymes in HIV patients.
16. PubMed, Effect of tesamorelin in people with HIV with and without dorsocervical fat: post hoc analysis of phase III trial (PMID 36845310, Journal of Clinical and Translational Science 2023): Post hoc analysis of phase 3 trial data characterized additional patient subgroups and safety findings including fluid retention and paresthesia.
17. PubMed, Effects of tesamorelin on inflammatory markers in HIV patients with excess abdominal fat (PMID 21516030, AIDS 2011): Tesamorelin's effect on inflammatory markers was associated with the degree of visceral adipose tissue reduction.
18. FDA, Bulk drug substances used in compounding under section 503A: Regulatory status of substances used in compounding, as distinct from FDA-approved drug products, is governed by the 503A/503B bulk drug substance framework.